Cencora, Inc. logo
Cencora, Inc. (COR)
Compare

Cencora, Inc. (COR) Return on Assets (ROA): 3.12%

Is Cencora, Inc.’s return on assets (ROA) high or low?

Cencora, Inc.'s return on assets (ROA) of 3.12% is 269% above its 5-year average of 0.85%, near the high end of its 5-year range (-7.68%–3.12%).

As of Saturday, June 13, 2026. 45.79% above its 12-month average of 2.14%.

COR Return on Assets (ROA) Chart

COR Return on Assets (ROA)
2.03%-9.78% 1Y
Zoom

COR Average Return on Assets (ROA) Chart

COR Current vs Average Return on Assets (ROA) Chart

COR Return on Assets (ROA) Metrics

RETURN ON ASSETS (ROA)

3.12%

RETURN ON ASSETS (ROA) AVG TTM

2.14%

RETURN ON ASSETS (ROA) AVG 3Y

2.52%

RETURN ON ASSETS (ROA) AVG 5Y

0.85%

RETURN ON ASSETS (ROA) AVG 10Y

1.51%

RETURN ON ASSETS (ROA) AVG 15Y

2.12%

RETURN ON ASSETS (ROA) AVG 20Y

2.38%

CURRENT VS TTM AVG

+45.79%

CURRENT VS 3Y AVG

+23.93%

CURRENT VS 5Y AVG

+268.50%

CURRENT VS 10Y AVG

+106.87%

CURRENT VS 15Y AVG

+47.04%

CURRENT VS 20Y AVG

+31.09%

COR Competitors' Return on Assets (ROA)

NAMEMARKET CAPRETURN ON ASSETS (ROA)TTM3Y5Y
Cencora, Inc. (COR)$54.80B3.12%2.14%2.52%0.85%
Becton, Dickinson and Company (BDX)$52.98B2.24%3.00%3.04%2.95%
Regeneron Pharmaceuticals, Inc. (REGN)$63.06B10.82%11.40%12.40%16.97%
Humana Inc. (HUM)$45.53B2.04%2.52%4.20%5.49%
IDEXX Laboratories, Inc. (IDXX)$44.24B32.35%29.29%27.30%27.52%
Agilent Technologies, Inc. (A)$36.67B10.82%10.56%11.14%10.55%
Zoetis Inc. (ZTS)$33.36B17.44%17.37%16.33%15.33%
Centene Corporation (CNC)$32.19B-7.94%-2.29%0.04%0.75%
Medline Inc. (MDLN)$30.96B2.47%3.17%1.75%1.75%
Cigna Corporation (CI)$78.83B4.10%2.99%3.50%3.82%

Asset Efficiency

ROA

3.1%

ROE

75.0%

Cencora, Inc. Return on Assets (ROA) Formula & Definition

ROA = Net Income / Total Assets

Return on assets measures how efficiently a company generates profit from its total assets.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Cencora, Inc. Return on Assets (ROA) FAQ

What is the return on assets (ROA) for Cencora, Inc. (COR)?
The return on assets (ROA) for COR stock is 3.12%.
Is Cencora, Inc.'s return on assets (ROA) high or low?
Cencora, Inc.'s return on assets (ROA) of 3.12% is 269% above its 5-year average of 0.85%, near the high end of its 5-year range (-7.68%–3.12%).
What is the TTM average return on assets (ROA) for Cencora, Inc. (COR)?
The TTM average return on assets (ROA) for COR stock is 2.14%.
What is the 3Y average return on assets (ROA) for Cencora, Inc. (COR)?
The 3Y average return on assets (ROA) for COR stock is 2.52%.
What is the 5Y average return on assets (ROA) for Cencora, Inc. (COR)?
The 5Y average return on assets (ROA) for COR stock is 0.85%.
What is the 10Y average return on assets (ROA) for Cencora, Inc. (COR)?
The 10Y average return on assets (ROA) for COR stock is 1.51%.
What is the 15Y average return on assets (ROA) for Cencora, Inc. (COR)?
The 15Y average return on assets (ROA) for COR stock is 2.12%.
What is the 20Y average return on assets (ROA) for Cencora, Inc. (COR)?
The 20Y average return on assets (ROA) for COR stock is 2.38%.

Cencora, Inc. Return on Assets (ROA) History

DATERETURN ON ASSETS (ROA)
2025-09-302.03%
2024-09-302.25%
2023-09-302.79%
2022-09-303.00%
2021-09-302.69%
2020-09-30-7.68%
2019-09-302.18%
2018-09-304.40%
2017-09-301.17%
2016-09-304.25%
2015-09-30-0.49%
2014-09-301.28%
2013-09-302.29%
2012-09-304.66%
2011-09-304.72%
2010-09-304.41%
2009-09-303.71%
2008-09-302.05%
2007-09-303.81%
2006-09-303.66%
2005-09-302.80%
2004-09-304.02%
2003-09-303.66%
2002-09-303.08%
2001-09-301.22%
2000-09-304.03%
1999-09-303.28%
1998-09-303.25%
1997-09-302.60%
1996-09-302.99%

About Cencora, Inc.

Cencora, Inc. functions as a global leader in the sourcing and distribution of pharmaceutical products, with operations spanning both the United States and international markets. Within its U.S. Healthcare Solutions segment, the company supplies a broad spectrum of pharmaceutical items, including generic and injectable medications, over-the-counter health products, and home healthcare equipment. Its extensive client network includes acute care hospitals, health systems, a variety of retail and mail-order pharmacies (independent, chain, long-term care), medical clinics, and other healthcare providers. This division also manages the distribution of crucial specialized pharmaceutical products like plasma, blood derivatives, and vaccines. Beyond product supply, Cencora offers comprehensive support services, such as pharmacy management, staffing solutions, and strategic consulting. It develops and implements supply management software, provides packaging services for both institutional and retail healthcare settings, and assists with clinical trial support, post-market approval processes, and commercialization strategies. For biotechnology and pharmaceutical manufacturers, the company delivers data analytics, outcomes research, and other specialized services. Furthermore, Cencora serves the animal health market, providing pharmaceuticals, vaccines, parasiticides, diagnostics, and micro feed ingredients for both companion and production animals. It also offers sales force support to manufacturers and specialized services to medical professionals, particularly oncologists, as well as to hospitals and dialysis clinics. The International Healthcare Solutions division concentrates on global pharmaceutical wholesale activities, associated services, and worldwide commercialization support. It ensures the efficient distribution of medicines, various healthcare goods, and related services to an international customer base comprising pharmacies, doctors, health centers, and hospitals. This segment also delivers specialized transportation and logistics solutions specifically designed for the biopharmaceutical sector. Founded in 1871, the company was formerly known as AmerisourceBergen Corporation before adopting the name Cencora, Inc. in August 2023. Its corporate headquarters are situated in Conshohocken, Pennsylvania.

Conshohocken, PA
47,000 employees
Healthcare / Medical - Distribution
Sector
Healthcare
Industry
Medical - Distribution
CEO
Robert Mauch